WE TAKE YOU

BEYOND
BIOPRINTING

A CHANGE IS COMING. ARE YOU READY?

 
WHO ARE WE

We are the first start-up to merge advanced electric, magnetic, & microfluidic 3D biofabrication technology with novel cyborganic technology to create high throughput tissues & organs with embedded bioelectronics, biosensors, and therapeutic agents.

We go beyond bioprinting to establish next generation applications in regenerative medicine, medical devices, & human-machine interfaces.

OUR VISION

We believe that increasing the number of advanced hybrid technologies available for commercial use will set the new quality benchmark of biofabricated products and unlock new, more complex applications in tissue engineering and regenerative medicine. Novel applications include cyborganics, biomechatronics, biosensors, biorobotics, and human-machine interfaces.

OUR MISSION

By developing and supplying up-to-date, cutting-edge technologies in biofabrication and tissue engineering, we want to offer complete, standardized processes to our customers and make the field of biofabrication more accessible to any working professional with a vision. We empower researchers, developers and producers in various promising fields, thus facilitating their journey from the lab benchtop to the market.

OUR TEAM

Ourobionics team brings business and industry experts together with academic experts. Together we have 50+ years of combined experience in research and corporate environment. 

JOHN ZANDBERGEN
Chief Executive Officer

photo.jpg

John is an entrepreneur with 20+ years of international business experience. He has held sales and marketing leading positions  with several companies before starting his own consultancy company providing business management and  business development services to companies in life sciences, IVD and medical devices.

1516304813698.jpg

PROF. SUWAN N. JAYASINGHE
Chief Scientific Officer

Suwan leads the BioPhysics Group at University College London. He has published over 150 publications in the field of tissue  engineering and regenerative medicine including documented evidence of how his inventions of 3D  bioelectrospraying, electrohydrodynamic jetting, and cell electrospinning overcome all of the limitations  associated with extrusion bioprinting. 

 

1517372565723.jpg

PROF. ALIREZA D. PIROUZ
Chief Technology Officer

Alireza is a professor at DTU Nanotech, Denmark, with over 90 publications  engineering, nanomaterials,  regenerative medicine and cyborganic technology. He is developing printable, moldable and electrically conductive materials with self-healing capacities for applications within the emerging fields of flexible electronics, cyborganics,  and soft robotics.

 

alvaro.jfif

PROF. ALVARO MATA
Chief Innovation Officer

Alvaro is the Chair in Biomedical Engineering & Biomaterials, University of  Nottingham specializing in in vitro biomimetic environments. He utilizes molecular printing within 3D environments to create dynamic and directed self-assembling systems, and molecularly-designed bioactive implants for applications in drug screening, regenerative medicine etc. He is the co-inventor of multiple biomaterial patents, including the first 4D self-assembly printable bioink.  

1615811061824.jfif

DR. STEPHEN G. GRAY
Co-Founder

Stephen is a serial entrepreneur with over 10 years of experience in 3D bioenginering with the strong skillset in data science, business intelligence, and non-dilutive funding assistance.  He is a co-inventor of merging electrospinning, electrohydrodynamic jetting of cells and bioelectrospraying with extrusion 3D bioprinting. 

 

Screenshot_20210420-212746_WhatsApp.jpg

ELPINIKI TSEKOU
Chief Financial Officer

Elpiniki holds a master’s degree in business economics and finance and has an extensive background in financial planning and financial controller role, with over 10 years of experience in investment and sustainability sector. She is currently the global liquidity manager at Booking.com and completing a financial engineering masters at KU Leuven.

 

1529009122380.jpg

DORIS ZORIC
Chief Marketing Officer

Doris is currently pursuing a PhD degree in structural biology at the University of Gothenburg, Sweden, and assisting several early-stage startup ventures. By integrating hands-on skills in graphic design, web design and marketing with her broad scientific background, she has successfully established the Ourobionics brand and co-ordinated communication across our outreach platforms.

Meet us in Pisa, Italy
on Sep 25-28
at BIOFABRICATION 2022

alvaro.jfif

PLENARY TALK

Prof Alvaro Mata
Univeristy of Nottingham, UK

 

Don't miss out on Ourobionics' 

co-founder and Chief Innovation Officer

Prof Alvaro Mara giving the plenary talk on bioinspired approaches to design and fabricate innovative materials, and devices for tissue engineering and regenerative medicine. Alvaro will be taking the floor on Monday Sep 26th in Verdi Theatre.

1615811061824.jfif

Dr Stephen G. Gray
Ourobionics, co-founder

 

On Wednesday Sep 28th our

co-founder and Chief Operational Officer Stephen G.Gray is giving a talk "A journey on building multiple start-ups in regenerative medicine, empowering academic entrepreneurship, & the emergence of 4D bioprinting & cyborganics to transform numerous industries”.

FViCUD_WAAEP0mt_edited.jpg
GIF DTP (2) (1).gif
Ourobionics announces its co-founding team and a strategic alliance with Invitech to multiplex advanced tissue engineering technologies with 3D bioprinting and cyborganics

We are officially presenting our co-founding team, formed by professionals with over 50 years of combined expertise in tissue engineering, 3D biofabrication, regenerative medicine, and cyborganics/human-machine interfaces. We have also entered a partnership with Invictech that sets the grounds for developing a multiplex 3D biofabrication platform.

Ourobionics becomes a distribution partner for Humabiologics products in Europe

We are happy to announce Ourobionics entered into a non-exclusive agreement with Humabiologics, a US biotech company specializing in the development and commercialization of human biomaterials for regenerative medicine research applications. The partnership agreement allows Humabiologics to respond to the growing demand and serve a broader life sciences customer base of industry partners and academic institutions in the European market.

 
 
NEWS
 

Thanks for submitting!